The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Macpac Holdings
Advised Super Retail Group on the acquisition of Macpac, the New Zealand-based outdoor adventure retailer
Pure Industrial Real Estate Trust
Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Godfrey Hirst
Advised Godfrey Hirst, the leading manufacturer, distributor and marketer of carpet and hard flooring in Australia and New Zealand, on its sale to Mohawk Industries, the NYSE-listed global flooring company
Jaybro
Advised Jaybro, a leading supplier of consumables to infrastructure contractors, on its sale to CHAMP Private Equity
Morris Corporation
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
Brookfield Canada Office Properties
Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.
Inenco Group Pty Ltd
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Lion’s Australian Premium Wine Business – Fine Wine Partners
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Whistler Blackcomb Holdings Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
Aegerion Pharmaceuticals
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
Patties Foods Ltd
Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement
Brasil/CT
Advised Brasil/CT on a capital injection made by Invest Tech in the Company. Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil. Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors
Divestment assets of Ball and Rexam
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam